Charles River Laboratories | CRL - Interest Expense On Debt

Stock Price
150.85
Daily Change
-8.27 -5.20%
Monthly
-14.75%
Yearly
7.01%
Q2 Forecast
147.82

Charles River Laboratories reported $26.74M in Interest Expense on Debt for its fiscal quarter ending in March of 2026.





Interest Expense On Debt Change Date
Agilent USD 25M 2M Dec/2025
Align Technology USD 16.04M 14.04M Dec/2025
Bio-Rad Laboratories USD 12.1M 200K Dec/2025
Bruker USD 8.1M 11.9M Dec/2025
Cardinal Health USD 101M 13M Mar/2026
Charles River Laboratories USD 26.74M 2.97M Mar/2026
Cigna USD 153.27B 4.65B Mar/2026
Concord Medical Services Hldg CNY 84.37M 32.34M Jun/2023
CVS Health USD 774M 13M Mar/2026
Danaher USD 63M 8M Mar/2026
Dentsply International USD 24M 2M Mar/2026
Elevance Health USD 357M 9M Mar/2026
Humana USD 193M 47M Mar/2026
Illumina USD 26M 1000K Dec/2025
Incyte USD 569K 13K Mar/2026
Intrexon USD 2K 5K Jun/2024
IQVIA Holdings USD 192M 1000K Mar/2026
Laboratory Of America USD 55.1M 100K Mar/2026
Lakefront Biotherapeutics EUR 1.72M 940K Sep/2025
Lonza CHF 84M 14M Jun/2025
McKesson USD 63M 11M Dec/2025
Merck EUR 121M 5M Dec/2025
Mettler Toledo International USD 17.39M 307K Dec/2025
Novartis USD 343M 39M Mar/2026
Pfizer USD 671M 40M Mar/2026
Quest Diagnostics USD 69M 2M Sep/2025
Revvity USD 24.72M 1.2M Mar/2026
Thermo Fisher Scientific USD 354M 11M Mar/2026
United Therapeutics USD 3.1M 100K Dec/2025
UnitedHealth USD 955M 19M Mar/2026
Veradigm USD 1.25M 641K Sep/2022
Waters USD 42M 33.38M Mar/2026
West Pharmaceutical Services USD 1.9M 1.7M Mar/2026